摘要
目的:探讨恩度联合化疗和单纯化疗治疗中晚期非小细胞肺癌的疗效和不良反应。方法:收治中晚期非小细胞肺癌患者86例,分为对照组和观察组。对照组采用单纯化疗,观察组采用恩度联合化疗。结果:观察组治疗有效率和不良反应发生率均显著优于对照组(P<0.05)。结论:恩度联合化疗治疗中晚期非小细胞肺癌的疗效显著,安全性高。
Objective:To explore the curative effect and adverse reaction of endostar combined with chemotherapy and chemotherapy alone in the treatment of middle and advanced non-small cell lung cancer.Methods:86 patients with middle and advanced non-small cell lung cancer were selected.They were divided into the control group and the observation group.The control group was treated with chemotherapy,and the observation group was treated with endostar combined with chemotherapy.Results:In the observation group,the effective rate of treatment and the incidence of adverse reactions were significantly better than those of the control group(P<0.05).Conclusion:The curative effect of endostar combined with chemotherapy in the treatment of middle and advanced non-small cell lung cancer was significant,and the security was high.
出处
《中国社区医师》
2017年第31期35-36,共2页
Chinese Community Doctors
关键词
恩度联合化疗
单纯化疗
非小细胞肺癌
不良反应
Endostar combined with chemotherapy
Chemotherapy alone
Non-small cell lung cancer
Adverse reaction
